Cingulate Inc. Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount
Cingulate Inc. (CING) reported Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount of $4.10 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate · last filed 2026-08-13
- Cingulate Inc. effective income tax rate reconciliation, change in enacted tax rate, amount for the quarter ending 2026-06-30 was $4.10K, a 22.65% increase year-over-year.
- Cingulate Inc. effective income tax rate reconciliation, change in enacted tax rate, amount for the quarter ending 2026-03-31 was $6.54K, a 97.85% increase year-over-year.
- Cingulate Inc. effective income tax rate reconciliation, change in enacted tax rate, amount for the quarter ending 2025-06-30 was $3.35K.
- Cingulate Inc. effective income tax rate reconciliation, change in enacted tax rate, amount for the quarter ending 2025-03-31 was $3.30K.
- Cingulate Inc. effective income tax rate reconciliation, change in enacted tax rate, amount for fiscal 2025 was $15.37K, a 13.14% increase from fiscal 2024.
- Cingulate Inc. effective income tax rate reconciliation, change in enacted tax rate, amount for fiscal 2024 was $13.58K.
| Period end | Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount 3 month | Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount 6 month | Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount 12 month |
|---|---|---|---|
| 2026-06-30 | $4.10K 10-Q · filed 2026-08-13 | $10.64K 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $6.54K 10-Q · filed 2026-05-14 | ||
| 2025-12-31 | $15.37K 10-K · filed 2026-03-18 | ||
| 2025-06-30 | $3.35K 10-Q · filed 2026-08-13 | $6.65K 10-Q · filed 2026-08-13 | |
| 2025-03-31 | $3.30K 10-Q · filed 2026-05-14 | ||
| 2024-12-31 | $13.58K 10-K · filed 2026-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |